Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Thomson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
British Medical Bulletin|February 3, 2009
Hepatitis C virus: the growing challengeBrian J Thomson
Biopreservation and Biobanking|October 24, 2014
Nottingham Health Science Biobank: a sustainable bioresourceBalwir Matharoo-Ball, Brian J Thomson
Journal of Viral Hepatitis|February 1, 2019
Testing for hepatitis C virus infection in UK prisons: What actually happens?Kathryn Jack, Brian J Thomson, William L Irving
BMC Medical Genomics|April 18, 2019
Young adults' attitudes to sharing whole-genome sequencing information: a university-based surveyPepita Barnard, Sarah Sharples, Brian J Thomson, et al.
Gut|March 9, 2007
Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective studyKeith R Neal, , Sheena Ramsay, et al.
Antiviral Chemistry & Chemotherapy|April 19, 2017
Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirinKanwal Baloch, Liqiong Chen, Ameer A Memon, et al.
International Journal of Pharmaceutics|June 17, 2018
Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?Yasmin Abo-Zeid, Richard A Urbanowicz, Brian J Thomson, et al.
British Journal of Haematology|July 26, 2002
CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphomaAndrew P Haynes, Ian Daniels, Abdulmunem M Abhulayha, et al.
International Journal of Technology Assessment in Health Care|April 1, 2009
Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practiceMarina Grishchenko, Richard D Grieve, Michael J Sweeting, et al.
The Journal of General Virology|December 26, 2001
Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severityRebecca Curran, Claire L Jameson, Joanna K Craggs, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
British Medical Bulletin|February 3, 2009
Hepatitis C virus: the growing challengeBrian J Thomson
Biopreservation and Biobanking|October 24, 2014
Nottingham Health Science Biobank: a sustainable bioresourceBalwir Matharoo-Ball, Brian J Thomson
Journal of Viral Hepatitis|February 1, 2019
Testing for hepatitis C virus infection in UK prisons: What actually happens?Kathryn Jack, Brian J Thomson, William L Irving
BMC Medical Genomics|April 18, 2019
Young adults' attitudes to sharing whole-genome sequencing information: a university-based surveyPepita Barnard, Sarah Sharples, Brian J Thomson, et al.
Gut|March 9, 2007
Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective studyKeith R Neal, , Sheena Ramsay, et al.
Antiviral Chemistry & Chemotherapy|April 19, 2017
Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirinKanwal Baloch, Liqiong Chen, Ameer A Memon, et al.
International Journal of Pharmaceutics|June 17, 2018
Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?Yasmin Abo-Zeid, Richard A Urbanowicz, Brian J Thomson, et al.
British Journal of Haematology|July 26, 2002
CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphomaAndrew P Haynes, Ian Daniels, Abdulmunem M Abhulayha, et al.
International Journal of Technology Assessment in Health Care|April 1, 2009
Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practiceMarina Grishchenko, Richard D Grieve, Michael J Sweeting, et al.
The Journal of General Virology|December 26, 2001
Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severityRebecca Curran, Claire L Jameson, Joanna K Craggs, et al.
Pageof 2